Clinical Trial News and Research

RSS

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration approved the new drug application for Tresiba (insulin degludec injection), a once-daily, long-acting basal insulin. Tresiba is indicated for use alone, or in combination with oral antidiabetic medicines or bolus insulin, and is approved for glycemic control in adults with type 1 and type 2 diabetes. Tresiba provides a long duration of action beyond 42 hours.

From Novo Nordisk 26 Sep 2015

Researchers develop new blood test to diagnose coeliac disease

Diagnosis of coeliac disease requires a tissue sample from the small intestine, which can be extremely unpleasant. Researchers at the Faculty of Medicine have developed a blood test which provides a rapid, painless answer.

25 Sep 2015

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology.

24 Sep 2015

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).

24 Sep 2015

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

For the past 27 years, cord blood transplants have been a life-saving treatment option for thousands of people with leukemia, non-Hodgkins lymphoma, Hodgkins disease and myelodysplastic disorders. Cord blood helps replace cancerous blood cells and replenish a patient's own bone marrow and immune system. Even with its success, researchers are continually looking for ways to improve the transplant process and increase cure rates.

24 Sep 2015

Discovery opens door to more targeted, effective treatments for cancer

In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.

24 Sep 2015

Study raises questions about direct applicability of clinical trial data for cancer drugs

When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients that ultimately take the drugs, raising questions about the direct applicability of trial data.

24 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

UNC Lineberger earns 'exceptional' rating from NCI for major grant application

The UNC Lineberger Comprehensive Cancer Center earned an "exceptional" rating from the National Cancer Institute for a major grant application associated with the center's multidisciplinary research.

23 Sep 2015

New, FDA-approved device provides minimally invasive approach to chronic GERD

Approximately 20 million Americans will experience some type of gastroesophageal reflux disease, or GERD, in their lives. In some cases, patients suffer resulting heart burn or acid regurgitation so severe that they require surgery to repair damage to their esophagus.

23 Sep 2015

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Longing to find a cure for cancer, HIV and other yet incurable diseases, researchers have already tried out hundreds of drugs, each requiring preclinical and clinical testing with live subjects. How many chemical agents more to try? Moving at such rate, will we find the cure during our lifetime? One of the easiest ways to speed up the drug development process is to simply perform it outside of the living body (e.g., by watching the substances react with the smallest pieces of live tissue and thus quickly predicting the overall effect it will make to the body when inside).

23 Sep 2015

Medinol announces completion of enrollment in BIONICS trial to evaluate effectiveness of eDES

Medinol, a developer of Interventional Cardiology devices, announced today the completion of enrollment in its BIONICS trial, a global, prospective, randomized, multicenter, clinical trial designed to evaluate the safety and effectiveness of a new Coronary Stent System, the first ever elastomeric Drug Eluting Stent or eDES.

22 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

Researchers develop biophysical treatment method for dialysis patients

Researchers at Charité -- Universitätsmedizin Berlin have developed a biophysical treatment method that allows up to 50 percent more toxins to be removed from the blood of dialysis patients. Use of this technology may result in patients with kidney disease seeing a considerable reduction in the length of dialysis sessions. An initial patent application for this technology was filed in 2011.

21 Sep 2015

Salsalate drug offers new hope for treating Alzheimer's disease and FTD

Scientists from the Gladstone Institutes have discovered that salsalate, a drug used to treat rheumatoid arthritis, effectively reversed tau-related dysfunction in an animal model of frontotemporal dementia (FTD). Salsalate prevented the accumulation of tau in the brain and protected against cognitive impairments resembling impairments seen in Alzheimer's disease and FTD.

21 Sep 2015

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.

21 Sep 2015

Invitae launches new education program to increase awareness of genetic testing for hereditary cancer

A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 less than half of the Americans surveyed said they were aware of genetic testing. Dubbed the "Angelina Jolie Effect," the current data highlight the far-reaching impact of Angelina Jolie's public discussion of genetic testing for hereditary cancer.

21 Sep 2015

Clinical Trial News and Research

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Researchers develop new blood test to diagnose coeliac disease

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

Discovery opens door to more targeted, effective treatments for cancer

Study raises questions about direct applicability of clinical trial data for cancer drugs

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

UNC Lineberger earns 'exceptional' rating from NCI for major grant application

New, FDA-approved device provides minimally invasive approach to chronic GERD

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Medinol announces completion of enrollment in BIONICS trial to evaluate effectiveness of eDES

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Researchers develop biophysical treatment method for dialysis patients

Salsalate drug offers new hope for treating Alzheimer's disease and FTD

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Invitae launches new education program to increase awareness of genetic testing for hereditary cancer

Enhanced pharmacist care improves outcomes in patients with high blood pressure

Aggressive blood pressure treatment can reduce risks of heart disease and death

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery